Research use only. This compound is supplied for in-vitro laboratory research by qualified researchers. It is not for human or veterinary consumption and has not been evaluated by the FDA.

Neuro Research
Oxytocin
Certificate pending · 10mg
10mg$60.00each
$6.00/mg
Oxytocin is a nine-residue cyclic peptide: a twenty-membered ring closed by a single disulfide, with a three-residue tail ending in a C-terminal amide. It is the smallest disulfide-constrained molecule in this catalogue.
The sequence is Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly with the C-terminal glycine amidated. Both structural features are recorded independently by two registries: UniProt P01178 annotates a disulfide between precursor residues 20 and 25, which are residues 1 and 6 of the nonapeptide, and a glycine amide at residue 9, while FDA GSRS records the same bridge and the same glycinamide conversion. There is no acetylation and no non-standard residue.
The single disulfide is the entire conformational constraint. Reducing it leaves a floppy linear nonapeptide about two daltons heavier, which is a useful marker in a reduction check. Pro7 sits at the hinge between the ring and the acyclic tail and restricts how that tail can move.
The molecule carries one tyrosine, at position 2, and no tryptophan or phenylalanine. That single aromatic residue plus the cystine makes absorbance at 280 nm workable but weak, and Tyr2 also provides the intrinsic fluorescence that Hawe and colleagues used as a stability readout. There is no methionine; the two cysteines are consumed by the disulfide, so exchange rather than free-thiol oxidation is the relevant chemistry.
Tyr2 does more than absorb light. In the copper complex characterised by Alshanski and colleagues in 2021 by paramagnetic relaxation enhancement NMR, the N-terminal amine is required for binding and the tyrosine ring then forms a cation-pi interaction with the metal.
Its receptor is OXTR (UniProt P30559), a class A G-protein-coupled receptor, resolved by X-ray at 3.2 Angstrom as PDB 6TPK and by cryo-electron microscopy at 2.9 Angstrom bound to a heterotrimeric G protein as PDB 7RYC. Binding to the three vasopressin receptors AVPR1A, AVPR1B and AVPR2 (UniProt P37288, P47901 and P30518) is documented rather than incidental, and UniProt's own mutagenesis annotation quantifies how a single substitution separates them.
Two masses circulate for this compound and they describe different materials. The figure above is the free peptide. The one-to-one acetate salt, registered separately under CAS 6233-83-6, is sixty daltons heavier because it carries one molecule of acetic acid. FDA GSRS also publishes a molecular-formula text field for both forms that is chemically impossible, so the formula above is taken from PubChem CID 439302 instead.
Certificate pending for the 10mg lot.The signed report will be published here as soon as the laboratory returns it.
Ordering at volume or on a schedule?
Request a supply quote →Buy more of this strength and the price comes down. The store applies it at checkout - there is nothing to enter.
Free US shipping - no minimum
Tell us the lot number and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Tell us the lot number and what you observed. If independent testing shows a discrepancy against our published certificate, we refund the lot in full and pull it from sale pending investigation.
Certificate pending
Discreet packaging
Dispatched within one business day
Free US shipping, no minimum
Compound information
- Type
- Neuro Research
- CAS number
- 50-56-6
- Molecular formula
- C43H66N12O12S2
- Molecular weight
- 1007.2 g/mol
- Sequence
- Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2 (CYIQNCPLG, cyclic 1-6 disulfide)
- Form
- Lyophilized powder
- Vial strength
- 10mg
- Catalogue number
- PX-OXY-10MG
- Purity
- Certificate pending for this strength
Identifiers are published properties of the molecule. Values we cannot confirm are omitted rather than estimated.
Research overview
A nine-residue peptide whose first and sixth residues are cysteines joined by a disulfide bridge, closing six of the nine into a ring with a three-residue tail. The bridge is drawn as a real bond between the two sulphurs, and neither carries a thiol hydrogen because a cystine has none.
- Residues
- 9
- Atoms
- 69
Primary literature
We have not compiled a reading list for this compound, and would rather show nothing than pad one out.
No public database record resolved for this compound under its catalogue name either. Rather than point you at a search that returns something else, this section stays empty.
PubMed, PubChem and ClinicalTrials.gov are independent scientific databases. A record or a published paper is not an endorsement of this product, and nothing indexed there describes an application, dose or outcome supported by PepXtide.
Storage & handling
Lyophilized
Store lyophilized at -20C, protected from light and moisture. This compound has the best-characterised degradation profile in the catalogue, from an accelerated study by Hawe and colleagues published in Pharmaceutical Research in 2009: it is most stable near pH 4.5, and degrades fastest at pH 9.0, then pH 7.0, then pH 2.0. Below pH 3 the routes are deamidation of Gln4, Asn5 and the C-terminal glycinamide; at and above pH 4.5 they are tri- and tetrasulfide formation, disulfide-linked and dityrosine-linked dimers, beta-elimination and larger aggregates. Two buffer cautions follow from the literature. Poole and colleagues reported in 2011 that citrate buffers form covalent citrate adducts at the N-terminal amine between pH 3 and 6, worst at pH 4 to 4.5 - which collides directly with the pH of best stability - while acetate and phosphate do not. And Alshanski and colleagues showed in 2021 that copper coordinates the N-terminal amine together with Tyr2, Ile3 and Gln4, so trace metal in a buffer is not inert here..
Reconstituted
Refrigerate after reconstitution and use within the period appropriate to the material.
Safety & handling
Bench handling, not a dosing guide.
Intended use
Supplied strictly as a laboratory research material for in-vitro study by qualified researchers. Not for human or veterinary use, not for ingestion or injection, and not for any clinical or diagnostic application.
Personal protective equipment
Handle with gloves, eye protection and a laboratory coat. Weigh and transfer lyophilized powder in a ventilated enclosure to avoid generating an inhalable dust.
Reconstitution
Reconstitute against the diluent and volume appropriate to your protocol, adding solvent slowly down the vial wall rather than directly onto the pellet. Do not shake. This is a handling note, not a dosing guide.
Storage after opening
Once reconstituted, refrigerate and use within the period appropriate to the material. Avoid repeated freeze-thaw cycles, which degrade peptides faster than continuous storage at the listed temperature.
Disposal
Dispose of material and containers in accordance with your institution's chemical waste procedures and applicable local regulations.
Research notice
Supplied as a lyophilized powder for in-vitro laboratory research only. No statement on this page describes an application, benefit, dose, route or outcome. Descriptions are structural and mechanistic, and reference data such as CAS numbers and molecular formulas is published information about the compound itself, provided for identification. No measured result is shown for this strength because a certificate has not yet been published for its lot.


